208 related articles for article (PubMed ID: 1691137)
1. Adjuvant therapy for node-negative breast cancer: a cautious interpretation.
Henderson IC
Important Adv Oncol; 1990; ():199-216. PubMed ID: 1691137
[No Abstract] [Full Text] [Related]
2. Adjuvant therapy for node-negative breast cancer: a proactive view.
Glick JH
Important Adv Oncol; 1990; ():183-97. PubMed ID: 2182518
[No Abstract] [Full Text] [Related]
3. Systemic therapy in resectable breast cancer.
Bonadonna G; Valagussa P
Hematol Oncol Clin North Am; 1989 Dec; 3(4):727-42. PubMed ID: 2691496
[TBL] [Abstract][Full Text] [Related]
4. [Medical treatment of breast carcinoma].
Rosso R; Gardin G
Ann Ital Chir; 1991; 62(5):467-77. PubMed ID: 1801625
[No Abstract] [Full Text] [Related]
5. [Current trends in the treatment of primary breast cancer].
Letiagin VP
Vopr Onkol; 1998; 44(5):632-5. PubMed ID: 9884732
[No Abstract] [Full Text] [Related]
6. [Principles of adjuvant drug therapy in breast cancer].
Castiglione M; Schnürch HG; Bender HG; Goldhirsch A
Gynakologe; 1994 Apr; 27(2):49-63. PubMed ID: 8039743
[No Abstract] [Full Text] [Related]
7. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
8. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
9. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
Taghian AG; Jeong JH; Mamounas EP; Parda DS; Deutsch M; Costantino JP; Wolmark N
J Clin Oncol; 2006 Aug; 24(24):3927-32. PubMed ID: 16921044
[TBL] [Abstract][Full Text] [Related]
10. A decision analysis of the effect of avoiding axillary lymph node dissection in low risk women with invasive breast carcinoma.
Jackson JS; Olivotto IA; Wai M D E; Grau C; Mates D; Ragaz J
Cancer; 2000 Apr; 88(8):1852-62. PubMed ID: 10760762
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment of breast cancer.
Akerley WL
R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
[No Abstract] [Full Text] [Related]
12. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
14. [What is the benefit of adjuvant therapy in breast cancer?].
Sauer H
Fortschr Med; 1992 Nov; 110(30):16-8, 20. PubMed ID: 1468737
[No Abstract] [Full Text] [Related]
15. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer.
Bonadonna G; Valagussa P; Tancini G; Rossi A; Brambilla C; Zambetti M; Bignami P; Di Fronzo G; Silvestrini R
NCI Monogr; 1986; (1):45-9. PubMed ID: 3534590
[TBL] [Abstract][Full Text] [Related]
16. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
[TBL] [Abstract][Full Text] [Related]
18. Late effects of adjuvant therapy for breast cancer.
Shapiro CL; Recht A
J Natl Cancer Inst Monogr; 1994; (16):101-12. PubMed ID: 7999452
[No Abstract] [Full Text] [Related]
19. Herceptin in early breast cancer: a call for judicious use.
Thorat MA
Natl Med J India; 2005; 18(6):315-7. PubMed ID: 16483033
[No Abstract] [Full Text] [Related]
20. Sentinel node in the era of neoadjuvant therapy and locally advanced breast cancer.
Trocha SD; Giuliano AE
Surg Oncol; 2003 Dec; 12(4):271-6. PubMed ID: 14998567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
